* Activated Cell Therapy Inc., of Mountain View, Calif., receivedFDA clearance for its 510(k) application to market the company'scell processing devices used to separate and enrich specific cells,such as stem cells and dendritic cells.
* Agouron Pharmaceuticals Inc., of La Jolla, Calif., received FDAapproval to begin Phase I trials of an anti-cancer drug, AG2034,which is a small-molecule compound designed to inactivate anenzyme, called glycineamide ribonucleotide transformylase, involvedin cancer cell proliferation.
* Cypros Pharmaceutical Corp., of Carlsbad, Calif., said evaluationof a second group of heart bypass patients participating in theplacebo-controlled Phase II studies of CPC-111 revealed thosetreated with the drug experienced statistically significantimprovements in heart function following surgery. The company saidthe findings confirmed results of the first patient group. CPC-111 isdesigned to generate cellular energy in the absence of oxygen toprotect organs and tissues from damage caused by ischemicconditions.
* Oread Inc., of Lawrence, Kan., has agreed to acquire themanufacturing and laboratory facilities in Palo Alto, Calif., of RocheHolding Ltd.'s subsidiary, Syntex (USA) Inc. Financial terms werenot disclosed, but the companies said Syntex will be a minoritystockholder in Oread, which will continue drug production andformation operations at Roche's Palo Alto headquarters. Thecompanies said the deal, expected to be complete in November 1996,will enable Oread to offer contract services ranging from screeningpotential therapeutic molecules to commercial manufacturing ofdrugs. Roche, of Basel, Switzerland, bought Syntex in 1994.
* Paracelsian Inc., of Ithaca, N.Y., said it has developed an improvedmodel for studying the way HIV infects immune system cells. Theadvancement, which builds on research conducted at the NationalInstitutes of Health in Bethesda, Md., identifies signal transductionpathways used by the virus to kill T cells. Paracelsian is employingthe model to assess the effectiveness of its AIDS compound, AndroVir (PN355), and identify other compounds against the disease.
* Parexel International Corp., of Boston, and Lansal ClinicalPharmaceutics Ltd., of Tel Aviv, merged their contract researchorganizations. Parexel acquired the Israeli company in a stocktransaction. Specific terms were not disclosed.
* PerSeptive Biosystems Inc., of Framingham, Mass., issued 1.25million shares of stock valued at $10 million to Millipore Corp., ofBedford, Mass., as part of PerSeptive's August 1994 purchase ofMillipore's BioSearch division.
* Phyton Inc., of Ithaca, N.Y., raised $4 million in a privateplacement of stock, convertible debentures and warrants to a group ofinvestors led by the Biotechnology Value Fund L.P., of SanFrancisco. Phyton is developing drugs derived from plants. Under acollaboration with Bristol-Myers Squibb Co., of New York, Phyton isusing its technology to produce paclitaxel, the active ingredient inBristol-Myers' anticancer drug, Taxol. Some financing from theprivate placement was earmarked for Phyton's subsidiary, PhytonGmbH, of Ahrensburg, Germany, to complete the purchase of a plantcell culture facility.
(c) 1997 American Health Consultants. All rights reserved.